Emergent BioSolutions, Inc. has signed several agreements with the University of Oxford, GSK, and the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) respectively, for the manufacture of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) for use in a Phase I trial. The study will evaluate the safety of MVA EBOZ as a heterologous boost to GSK’s Chimp Adenovirus type 3 (ChAd3) Ebola vaccine candidate.   Emergent perfo...